Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H15ClNO4.Na |
Molecular Weight | 331.727 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC1=C(COC(C)(C)C([O-])=O)OC(=N1)C2=CC=C(Cl)C=C2
InChI
InChIKey=IXEKPMAYILRTFK-UHFFFAOYSA-M
InChI=1S/C15H16ClNO4.Na/c1-9-12(8-20-15(2,3)14(18)19)21-13(17-9)10-4-6-11(16)7-5-10;/h4-7H,8H2,1-3H3,(H,18,19);/q;+1/p-1
Molecular Formula | C15H15ClNO4 |
Molecular Weight | 308.737 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Romazarit, (Ro 31-3948, 7), 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methylpropionic acid is a substituted heterocyclic alkoxypropionic acid. Romazarit was considered to be a potential disease-modifying antirheumatic drug. Romazarit was withdrawn due to its toxicity profile.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
144 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2088768 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROMAZARIT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
958 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2088768 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROMAZARIT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Sample Use Guides
patients with rheumatoid arthritis:
200 mg or 450 mg every 12 h for up to 24 weeks,
100 mg t.i.d., 350 mg b.i.d., or 350 mg t.i.d., for 6 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2156999
In vitro romazarit was an extremely weak inhibitor of prostaglandin synthetase activity in both sheep seminal vesicle (IC50 6500 microM) and rat renal medulla (IC50 greater than 300 microM) cell-free preparations.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:09:32 GMT 2023
by
admin
on
Sat Dec 16 10:09:32 GMT 2023
|
Record UNII |
TK7BS24A7A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
109544-09-4
Created by
admin on Sat Dec 16 10:09:32 GMT 2023 , Edited by admin on Sat Dec 16 10:09:32 GMT 2023
|
PRIMARY | |||
|
TK7BS24A7A
Created by
admin on Sat Dec 16 10:09:32 GMT 2023 , Edited by admin on Sat Dec 16 10:09:32 GMT 2023
|
PRIMARY | |||
|
DTXSID30911236
Created by
admin on Sat Dec 16 10:09:32 GMT 2023 , Edited by admin on Sat Dec 16 10:09:32 GMT 2023
|
PRIMARY | |||
|
23663984
Created by
admin on Sat Dec 16 10:09:32 GMT 2023 , Edited by admin on Sat Dec 16 10:09:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|